Follow us...

 

Search News Archives

News Channels

 

Coronavirus (COVID-19)

 

 

View Channel

New Laboratory Products

 

View Channel

Lab News

 

View Channel

Research & Case Studies

 

View Channel

Microscopy | Image Analysis

 

View Channel

Separation Science

 

View Channel

Videos

 

View Channel

Events | Webinars

 

View Channel

Conferences | Events
The Native Antigen Company

The Native Antigen Company

The Native Antigen Company

Products

Contact The Native Antigen Company


If you have not logged into the website then please enter your details below.

All articles from The Native Antigen Company

  The Native Antigen Company Launches Range of SARS-CoV-2 Specific Antibodies

The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the introduction of ten new monoclonal antibodies recognising SARS-CoV-2, the causative agent of COVID-19. These ten antibodies recognise different epitopes of the SARS-CoV-2 Spike glycoprotein, nine of which are SARS-CoV-2-specific and do not cross-react with other human coronaviruses...

 

  New Collaboration to Increase COVID-19 Antigen Production for Diagnostic Kits and Vaccine Development

OXGENE™ and The Native Antigen Company have announced a collaboration to scale up production of SARS-CoV-2 (COVID-19) reagents by combining OXGENE’s proprietary Adenoviral Protein Machine Technology with The Native Antigen Company’s antigen development expertise. Together, OXGENE and The Native Antigen Company will aim to scale their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines...

 

  The Native Antigen Company Introduces Novel Coronavirus Antigens

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the commercial introduction of its Novel Coronavirus antigens, derived from the emerging Wuhan strain. These recombinant proteins offer scientists high-quality reagents to support ongoing infectious disease research, and the development of diagnostics and vaccines....

 

  The Native Antigen Company Signs Distribution Agreement with BIOZOL and Shanghai Bioleaf

The Native Antigen Company, one of the world’s leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases, announced today that it has appointed BIOZOL and Shanghai Bioleaf to distribute its high-quality products in Germany, Switzerland and Austria, and China, respectively.....

 

  The Native Antigen Company Launches new Zika Immunoassays with Unprecedented Specificity and Sensitivity

The Native Antigen Company has launched a series of ground-breaking immunoassays for Zika virus, offering researchers in academia, public health and drug discovery the capability to work with unprecedented levels of specificity and sensitivity. Unlike previous methods, the new assays have little or no cross-reactivity with other flaviviruses, including Dengue, West Nile, Yellow Fever, Japanese Encephalitis, Tick-Borne Encephalitis and Usutu virus...

 

  The Native Antigen Company Expands into New Development and Production Facilities and Introduces New Services

The Native Antigen Company (NAC) announce that it has relocated into larger facilities, in Oxfordshire, UK

the Native AntigenThe new building has purpose-built laboratories and doubles the Company’s manufacturing capacity. This will increase the speed of new product development within NAC’s core business of infectious disease antigens and antibodies. The new laboratory space also enables NAC to add custom immunoassays to its offering to support customer’s ELISA assay and lateral flow device requirements....

 

 

 

 

Media Partners